Cavitation Technologies, Inc. Form 10-K

 false 2025 FY 0001376793

 2024-12-31

 2025-09-26

 CVAT:NanoReactorsMember

 CVAT:NanoReactorsMember

 CVAT:LicenseFeeMember

 CVAT:LicenseFeeMember

 us-gaap: SalesRevenueNetMember
 CVAT:DesmetMember

 us-gaap: SalesRevenueNetMember
 CVAT:DesmetMember

 CVAT:VendorOneMember

 CVAT:VendorTwoMember

 CVAT:VendorOneMember

 CVAT:VendorTwoMember

 CVAT:VendorThreeMember

 CVAT:DesmetBallestraMember
 CVAT:LicensingRevenueMember

 CVAT:DesmetBallestraMember
 CVAT:NanoReactorsMember

 CVAT:DesmetBallestraMember
 CVAT:NanoReactorsMember

 CVAT:DesmetMember
 CVAT:PatentAssignmentAndLicenseBackAgreementMember

 2024-10-08
 2024-10-09

 us-gaap: OperatingSegmentsMember

 us-gaap: OperatingSegmentsMember

 CVAT:FormerOfficerAndCurrentOfficerMember

 2025-02-01

 CVAT:FormerOfficerAndCurrentOfficerMember

 CVAT:DifferenceInAccruedPayrollAndLiabilitiesMember

 CVAT:BoardMemberMember

 CVAT:BoardMemberMember

 CVAT:EIDLMember

 CVAT:EIDLMember

 CVAT:EIDLMember

 2020-07-01
 2020-07-31

 CVAT:EIDLMember

 2020-07-31

 CVAT:StockIssuedForServicesMember

 2025-06-09
 2025-06-10

 2024-11-01
 2024-11-30

 2025-02-01

 srt: MinimumMember

 2024-11-30

 srt: MinimumMember

 srt: MaximumMember

 2024-11-30

 srt: MaximumMember

 CVAT:BlackScholesOptionMember

 2024-11-01
 2024-11-30

 CVAT:BlackScholesOptionMember

 2025-02-01

 2025-02-01

 2022-07-01

 CVAT:WarrantPrice1Member

 CVAT:WarrantPrice1Member

 CVAT:WarrantPrice2Member

 CVAT:WarrantPrice2Member

 CVAT:WarrantPrice3Member

 CVAT:WarrantPrice3Member

 CVAT:WarrantPrice4Member

 CVAT:WarrantPrice4Member

 CVAT:WarrantPrice5Member

 CVAT:WarrantPrice5Member

 2025-04-01

 UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 FORM 10-K

 (Mark One)

 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. FROM THE TRANSITION PERIOD FROM _____ TO _____.

 For the fiscal year ended June
30, 2025

 Commission file number 000-53239

 Cavitation Technologies, Inc.

 (Exact name of Registrant
as Specified in its Charter)

 Nevada

 20-4907818

 (State or Other Jurisdiction of Incorporation or Organization)

 (I.R.S. Employer Identification No.)

 10019 CANOGA AVENUE, CHATSWORTH, CA LIFORNIA 91311
 (Address, including Zip Code, of Principal Executive Offices)

 ( 818) 718-0905
 (Registrant's Telephone Number, Including Area Code)

 SECURITIES REGISTERED PURSUANT
TO SECTION 12(b) OF THE ACT:

 NONE

 SECURITIES REGISTERED PURSUANT
TO SECTION 12(g) OF THE ACT:

 Title of Each Class:

 Name of Each Exchange on Which Registered:

 Common Stock, $0.001 par value

 Over the Counter (Bulletin Board)

 Indicate by check mark if
the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

 Indicate by check mark if
the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No

the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes No

the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
such files). Yes No

 Indicate by check mark if
disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best
of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K,
or any amendment to this Form 10-K.

the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging
growth company. See definitions of "large accelerated filer," "accelerated filer", "smaller reporting company"
and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

 Large accelerated filer

 Accelerated filer

 Non-accelerated filer

 Smaller reporting company

 Emerging growth company

 If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.

the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control
over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that
prepared or issued its audit report. Yes No

 If securities are registered pursuant to Section 12(b)
of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of
an error to previously issued financial statements.

 Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's
executive officers during the relevant recovery period pursuant to §240.10D-1(b).

the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No

 State the aggregate market value of the voting and
non-voting common equity held by non-affiliates of the registrant by reference to the price at which the common equity was last sold,
or of the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed
second fiscal quarter: $ 5,192,000 as of December 31, 2024 based on the closing price of $0.019 per share and 284,289,740 shares outstanding.

 The registrant had 289,156,340 shares
of common stock outstanding on September 26, 2025.

 DOCUMENTS INCORPORATED
BY REFERENCE:

 None

INC.

 FORM 10-K ANNUAL REPORT

 FOR THE YEAR ENDED JUNE
30, 2025

 Page

 Item 1. Business

 Item 1A. Risk Factors

 Item 1B. Unresolved Staff Comments

 Item 1C. Cybersecurity

 Item 2. Properties

 Item 3. Legal Proceedings

 Item 4. Mine Safety Disclosures

 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 Item 6. Reserved

 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

 Item 7A. Quantitative and Qualitative Disclosures About Market Risk

 Item 8. Financial Statements and Supplementary Data

 Item 9. Changes In and Disagreements With Accountants on Accounting and Financial Disclosure

 Item 9A. Controls and Procedures

 Item 9B. Other Information

 Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections

 Item 10. Directors, Executive Officers and Corporate Governance

 Item 11. Executive Compensation

 Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 Item 13. Certain Relationships and Related Transactions, and Director Independence

 Item 14. Principal Accounting Fees and Services

 Item 15. Exhibits, Financial Statement Schedules

 Item 16. Form 10-K Summary

 Signatures

 i

 CAUTIONARY NOTE REGARDING
FORWARD-LOOKING STATEMENTS

 This annual report on Form
10-K and the exhibits attached hereto contain "forward-looking" statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements concern our anticipated results and developments in our operations in future periods,
planned exploration and development of our properties, plans related to our business and matters that may occur in the future. These statements
relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and
assumptions of management. We use words like "expects," "believes," "intends," "anticipates,"
"plans," "targets," "projects" or "estimates" in this annual report. When used, these
words and other, similar words and phrases or statements that an event, action or result "will," "may," "could,"
or "should" result, occur, be taken or be achieved, identify "forward-looking" statements. Such forward-looking
statements are subject to certain risks and uncertainties, both known and unknown, and assumptions.

 Management has included projections
and estimates in this annual report, which are based primarily on management's experience in the industry, assessments of our results
of operations, discussions and negotiations with third parties and a review of information filed by our competitors with the Securities
and Exchange Commission or otherwise publicly available. We caution readers not to place undue reliance on any such forward-looking statements,
which speak only as of the date made. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events
or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events, except as required
by law. We qualify all of the forward-looking statements contained in this annual report by the foregoing cautionary statements.

 ii

 ITEM 1. BUSINESS

 Cavitation Technologies,
Inc. (referred to herein, unless otherwise indicated, as "the Company," "CTi," "we," "us,"
and "our") is a Nevada corporation originally incorporated under the name Bio Energy, Inc. We are a process and product development
firm that has developed, patented, and commercialized environmentally friendly technology-based systems that are designed to serve large,
growing, global markets such as vegetable oil refining, renewable fuels, water treatment, wines and spirits enhancement, algae oil extraction,
water-oil emulsions and crude oil yield improvement. Our systems are designed to process industrial liquids at a reduced processing time,
lower operating cost, improved yield while operating in environmentally friendly manner. Our patented Nano Reactor and LPN
were the critical components of our business and we have generated all of our previous revenue while utilizing these components.

 Vegetable Oil Refining

 Our first commercial application
for our technology has been the CTi Nano Neutralization System which has been utilized to improve edible vegetable
oil refining process. Our environment friendly process has been shown to reduce refining costs, increase oil yield, and limit the number
of chemical additives used in chemical refining of vegetables oils. This patented process (US Patent # 7,762,715 and # 8,042,989) is designed
to be incorporated into new and existing soybean, rapeseed, canola and palm vegetable oil refineries.

 Our first pilot test of our CTi
NANO Neutralization System was conducted in 2010 at Carolina Soya, a 200-metric ton/day crude soy oil refining plant in
Estill, South Carolina. Our second system, which became operational in fiscal 2011, has been continuously utilized since 2011 at the plant
that processes approximately 450 metric tons per day of soy oil. Further, we have successfully shipped over 200 systems domestically and
internationally. We also continuously focus on developing additional Nano Reactor applications and managing the
intellectual property issues associated with new processes and applications.

 Desmet Belgium Group (previously
Desmet Ballestra) Agreement

 Desmet, together with its
affiliates, is a global engineering and equipment supply firm engaged in the development, design and supply of process equipment for oils
and fats processing facilities including vegetable oil refining, biofuel, oleo chemical, seed crushing, surfactant and detergent markets.
Desmet supplies these markets with services based on the latest globally sourced technologies. Desmet has relationships with major refiners
globally. A significant portion of global vegetable oil refineries include major refiners such as Archer Daniels Midland Company, Cargill,
Inc. and Bunge Limited. Desmet has more than 40 sales representatives selling in North America, South America, Europe, and Asia. Since
its founding in 1946, Desmet reports that it has built a global network that includes 1,300 employees, 17 global and 8 representative
offices, and more than 6,000 lines in a variety of applications. Desmet operates a separate division for each of the above markets and
the Desmet Oils & Fats division has supplied small and large plants to approximately 1,900 oil millers in 150 countries, covering
over 6,300 process sections.

 On May 14, 2012, we signed
a global R&D, Marketing and Technology License Agreement with Desmet Ballestra Group s.a. (Desmet), a Belgian company
that is actively marketing the NANO Neutralization System, the key component of which is our Nano Reactor to
soybean and other vegetable oil refiners. The Agreement provided Desmet (licensee) a limited, exclusive license and right to develop,
design and supply our NANO Neutralization System which incorporates Nano Reactor devices on
a global basis tools and fats and oleo chemical applications. The agreement expired in May 2015.

 On January 22, 2016, Desmet
and the Company executed a new three year License Agreement with essentially the same terms with the May 2012 agreement that was effective
August 1, 2015. As part of the agreement, Desmet provided, under certain conditions, limited monthly advance payments of $50,000 to be
applied against gross profit share from future sales. The agreement expired in August 2018.

 On October 1, 2018, Desmet
and the Company executed a new three year License Agreement with essentially the same terms with the January 2016 agreement. As part
of the agreement, Desmet provided us under certain conditions, limited monthly advances of $50,000 through October 1, 2021, to be applied
against gross profit share from future sales. The agreement expired in October 2021.

 On October 1, 2021, Desmet
and the Company executed a new three-year License Agreement with essentially the same terms with the October 2018 agreement. As part of
the agreement, Desmet provided the Company monthly advances of $40,000 through November 1, 2024, that was applied as payment from reactor
sales, however, the Company was no longer entitled to gross profit share from future sales. This agreement was terminated and replaced
in February 2024.

 On February 15, 2024,
Desmet and the Company terminated the October 2021 agreement and executed a new but similar three-year agreement ("February 2024
agreement"). As part of the February 2024 Agreement, Desmet will provide the Company monthly advances of $25,000 through February
2027, subject to limitations, that will be applied as payment from future reactor sales. In addition, Desmet also waived reimbursement
right for the outstanding advances made pursuant to the October 2021 agreement in the aggregate and up to $498,000.

 In October 2024, we entered into a Patent Assignment
and License Back Agreement with Desmet to assign certain patents, intellectual property rights and trademarks related to vegetable oil
refining to Desmet, as consideration for the patent assignments, Desmet paid the Company $880,000 in cash. This transaction provided capital
for continuous operations and business development of our company. This agreement effectively superseded the February 2024 agreement with
Desmet including the termination of the monthly advances of $25,000.

 Key points of the October 2024 Agreement included:

 Reserved License: we retained a worldwide, exclusive, transferable, and royalty-free license to practice and use the Assigned Patents in the fields of water and wastewater processing, recovery, recycling, and purification (including oilfield wastewater), as well as the manufacture, distillation, brewing, enhancement, sale, and marketing of alcoholic beverages (the "Licensed Fields").

 Grant-Back License: we received a worldwide, exclusive, transferable, and royalty-free license to practice and use the Assigned Patents and associated technical information, consistent with the scope of the Reserved License.

 Trademark Usage: we retained exclusive rights to use the "Nano Reactor " mark for our businesses, systems, and products related to the Licensed Fields.

 Under both the Reserved License and the Grant-Back
License, the Company will have a worldwide, exclusive, transferable, and royalty-free license and right to design, build, use, export,
improve, sell, and market Nano Reactor devices, as well as Nano Reactor systems and products that incorporate or utilize Nano
Reactor devices, limited to uses and applications within one or more of the Licensed Fields.

 As a result of this agreement, the Company expects
that Desmet will start to manufacture the Nano reactors by itself and sale of Nano reactors to Desmet by the Company will significantly
be reduced in future periods. We will continue to own and operate a large portfolio of patents and intellectual property rights
in applications not related to vegetable oil refining. The following are Management's plans going forward to generate revenues and
sustain the operations of the Company and its current status:

 1.

 Water Treatment and Remediation in the Permian Basin

 2.

 Water Remediation and Disinfection in Agriculture

 3.

 Business Venture with Alchemy Beverages, Inc.

 4.

 New Technologies: Hydro-Plasma

1. Water Treatment and Remediation in the Permian Basin

 Enviro Watertek, LLC

 In April 2019, the
Company and Delaware Water Company, LLC (Delaware) formed a limited liability company called Enviro WaterTek LLC
("Enviro","EW"). Enviro is owned 50% by the Company and 50% by Delaware, and the Company accounts for its
investment in Enviro under the equity method of accounting. From 2019 to 2024, Enviro had insignificant operations. This agreement
covers our first commercial entrance into industrial treatment of produced and frac water. Fracking industry has seen a significant
growth over the past ten years, reaching daily water consumption volume of over 58 million barrels per day. Our newly designed Low
Pressure Nano Reactor ( LPN) was specifically developed to be integrated into produced water treatment system along
with our proprietary chemical formulations, and has depicted measurable and quantifiable advantages over industry standard processes
and equipment. Our agreement with EW provides for sales on LPN plus recurring revenue stream based on processing of
produced and frac water volumes and utilization. Our agreement with EW has a fifteen-year term.

 In March 2020, the global
pandemic of COVID-19 had a negative impact on the oil and gas industry worldwide, and has consequently impaired our ability to rapidly
accelerate LPN sales and recurring revenue stream. Our current operations are limited to system trials and have not
produced any meaningful revenue. The system has the capacity to treat approximately 17,000 barrels of produced water per day (BPD).

 In June 2023, the Company
determined that investment in EW was impaired, and as a result, the Company recorded an impairment charge of approximately $1.1 million.
There were no transactions during fiscals 2025 and 2024, from sale of reactors and usage fee.

 Currently, we have installed our system at a major
water remediation company in Texas, where it has been in place for over six months, with more testing required. We continue to pursue
additional customers, primarily in the Permian Basin.

 What differentiates us in the industry:

 No chemical usage in water remediation, significantly reducing operational costs.

 Integration into existing processes within 24 hours, without disrupting ongoing operations.

 Compact systems with minimal energy consumption.

 Post-treatment water can be either reused or safely disposed of.

 The Company anticipates that sales will be generated
in the first half of fiscal 2026.

 2. Water Remediation and
Disinfection in Agriculture

 In 2024, we installed our
first system at Hacienda Farms (B&F Greenhouse Services, Inc.) in Canada. The system is currently undergoing trials to increase oxygen
levels in the water, eliminate algae, and control bacterial growth, all without the use of harsh chemicals. This innovative technology
is designed to improve water quality and promote healthier crop growth.

 Hacienda Farms, relies heavily
on water from Lake Erie, which poses significant water remediation challenges due to issues like algae and bacterial contamination. Additionally,
Hacienda Farms has been dealing with high sodium levels in the water, which affect calcium absorption in plants, and fungal issues that
harm root health, ultimately reducing crop yields. These water quality challenges necessitate advanced remediation solutions to ensure
the sustainability and productivity of their greenhouse operations. Our technology addresses these problems by controlling microorganisms,
accelerating vegetative and root growth, and increasing overall plant biomass. This not only improves crop production but also supports
sustainable farming practices.

 The overall market for water
treatment in Canada is valued at approximately $2.51 billion, with continuous expansion due to the demand for sustainable solutions in
agriculture and industrial applications.

 The outcome of the trials
mentioned above, which we expect to be completed within the first calendar quarter of 2026, will determine the commercial viability of
our product and the timeline for any potential revenue generation.

 3. Business Venture with Alchemy Beverages, Inc.

 In fiscal 2014, Roman Gordon,
one of our shareholders and a former officer, formed a company, Cameo USA LLC (Cameo). Since its formation, Cameo has had no revenue,
no operations, and has had no assets or liabilities. On June 4, 2018, Mr. Gordon contributed his 100% interest in Cameo to Cavitation
Technologies, Inc. As Mr. Gordon had no reasonable and objectively supportable basis in the valuation of his investment in Cameo, there
was no value assigned to the contribution of Cameo.

 On June 29, 2018, we agreed
to license Cameo to Alchemy Beverages Inc. ("ABI"). In addition, we have agreed to provide certain licensing rights related
to our miniature low pressure nano-reactor (MLPN) to be used in developing and manufacturing of small home appliances to enhance alcoholic
beverages. In consideration for these ABI has agreed to issue 19.9% of ABI's outstanding common shares to us (limited to 20 million
shares of ABI). ABI is a private company and in the business of producing and selling alcoholic beverages, equipment, and home appliances.
Prior to this agreement, ABI was independent of CTI and had no relation to us nor to our management.

 Pursuant to the licensing
agreements, ABI will have the exclusive global marketing and distribution rights of Cameo and our patented and patent pending technologies
for the processing of alcoholic beverages. We have agreed to assist in the installation and maintenance of the MLPN to ABI and will receive
royalty payments ranging from 1% to 3% on all net revenues, as defined in our license agreement for the life of the applicable patents.
In addition, we will receive leasing, consulting, and manufacturing fees as defined in the licensing agreement.

 Over the past several years, we have worked closely
with ABI to develop the smart home kitchen appliance Barmuze and alcoholic beverages. Significant work has been done on Barmuze branding,
including launching a new website and creating animations throughout the year to showcase how the appliance works. ABI is actively pursuing
the commercial production of Barmuze, licensing the technology to third parties, and considering the opportunity to develop its own alcohol
brands, leveraging our cutting-edge technology to transform any alcohol into a smooth, top-shelf experience.

 ABI is in the process of
completing its financial audit, which is estimated to be completed before the end of the first quarter of fiscal 2026, engaging focus
groups for Barmuze acceptance, refining marketing and distribution strategies, and securing additional capital for production. The Company
also plans on obtaining additional financing in early fiscal 2026

 As of June 30, 2025 and the date of this report, ABI
has not generated any sales under Cameo brand. The earliest sales and revenue for Barmuze are anticipated in the second half of 2026.
Also, ABI is working on creating its own line of alcoholic beverages and licensing of the technology to other brands. For more information,
www.alchemybeveragesinc.com and www.barmuze.com.

 During fiscals 2025 and 2024,
there were no sales or royalties generated pertaining to our agreement with Alchemy Beverages, Inc. The investment in ABI has no value
assigned to it, which approximates its fair value.

 4. New Technologies: Hydro-Plasma

 Along with improving our existing technologies, we
have developed Hydroplasma, an innovative process combining cavitation and cold plasma technology to enhance our water treatment efficiency,
which:

 Breaks down both organic and inorganic compounds.

 Is highly scalable – from 15 to 40 GPM.

 Eliminates microorganisms and diseases.

 Has multiple industrial applications.

 The technology is patent pending.

 This cutting-edge technology creates reactive agents,
such as hydroxyl radicals and hydrogen peroxide, that break down pollutants, bacteria, and viruses in water more effectively than traditional
methods. It's an environmentally friendly and scalable solution, with applications in water treatment, agriculture, sulfur removal
from bunker fuel, and more.

 The global cold plasma market is projected to
grow from $1.5 billion in 2021 to $3.1 billion by 2027, fueled by increasing demand for sustainable water solutions. Our technology has
the potential to revolutionize water treatment on a global scale. To accelerate this development, we have established partnerships with
New Mexico State University, the University of Guadalajara, and the Brackish Groundwater National Desalination Research Facility (BGNDRF),
NM, to collaborate on water remediation programs.

 In order to develop these markets we may need additional
funding, and may attempt to raise additional debt and/or equity financing to fund operations and additional working capital. However,
there is no assurance that we will be successful in obtaining such financing or obtain sufficient amounts necessary to meet our business
needs, or that we will be able to meet our future contractual obligations.

 Testing of the technology is currently underway. Upon
completion of multiple trials, if successful, sales and revenue are anticipated in the first half of fiscal 2026.

 Customers Dependence

 Prior to entering into the
Patent Assignment and License Back Agreement, we sold our industrial capacity Nano Reactor and Nano Neutralization
System through our strategic partner Desmet and most of our revenue for the fiscal years ended June 30, 2025 and 2024, was derived
from sales of reactors to Desmet. We have generated no revenue pertaining to our licensing agreement with EW in our fiscals 2025 and 2024.

 Sources and availability
of raw materials and the names of principal suppliers

 We have historically sourced
reactor components from various domestic and international suppliers. We do not have any long-term contracts, agreements, or commitments
with any supplier. We believe it would take approximately 30 days to find a new supplier, if necessary.

 Competition

 Our competitors in produced
and frac water treatment application range from local service providers to multi-national global corporations with considerable financial
resources, engineering expertise, established and proven technologies. We believe that LPN is a conceptually new technology
that has not been introduced in the field of water treatment applications. LPN has demonstrated exceptional results
in treating produced and frac water commercially, significantly reducing the usage of hazards chemicals during the process, meanwhile,
achieving desirable water quality for industrial re-use or disposal, although, the acceptance of the technology has been slow.

 Patents

 As
of June 30, 2025, our portfolio of patents included 16 issued patents in the United States and 11 issued patents internationally.
Our patents cover multiple process and applications of our technology in vegetable oil refining, production of biodiesel, treatment of
process and industrial water, upgrade of hydrocarbons and enhancing of alcoholic beverages. In October 2024, we assigned our patents
relating to vegetable oil refining to Desmet for a cash consideration of $880,000.

 We retained a worldwide, exclusive, transferable,
and royalty-free license to practice and use the Assigned Patents in the fields of water and wastewater processing, recovery, recycling,
and purification (including oilfield wastewater), as well as the manufacture, distillation, brewing, enhancement, sale, and marketing
of alcoholic beverages (the "Licensed Fields"). We also received a worldwide, exclusive, transferable, and royalty-free license
to practice and use the Assigned Patents and associated technical information, consistent with the scope of the Reserved License, in addition,
we retained exclusive rights to use the "Nano Reactor " mark for our businesses, systems, and products related to the
Licensed Fields.

 We continuously develop new
technologies and applications, as we have filed patent applications for Low Pressure Nano-Reactors LPN. LPN
is a highly efficient homogenizer and emulsifier that can be utilized in multiple fluids processing applications.

 Royalty Agreements

 On July 1, 2008, our wholly
owned subsidiary entered into Patent Assignment Agreements with two parties, our former President as well as former Chief Executive Officer
(CEO) who currently serves as our Technology Senior Manager, where certain devices and methods involved in our hydrodynamic cavitation
processes invented by the former President and former CEO/current Technology Senior Manager have been assigned to the subsidiary. In exchange,
that subsidiary agreed to pay a royalty of 5% of gross revenues to each of the former President and former CEO/current Technology Senior
Manager for licensing of the technology and leasing of the related equipment embodying the technology. These agreements were subsequently
assumed by us on May 13, 2010, from our subsidiary. Our former CEO/current Technology Senior Manager and former President both waived
their rights to receive royalty payments that have accrued, or that may accrue, on any gross revenue generated through June 30, 2025.

 On April 30, 2008 and as
amended on November 22, 2010, our wholly owned subsidiary entered into an employment agreement with its former Director of Chemical and
Analytical Department (the "Inventor") to pay, in the first year, an amount equal to 5% of actual gross revenue received by
us on any patent for which the Inventor was a legally named inventor, and, in each subsequent year, 3% of actual gross revenue received
by us on any such patent. Since entering into that employment agreement, and during the term of this employment agreement, we have not
recognized any revenue on any patents for which the Inventor was a legally named inventor.

 Governmental Approval
and Regulations and Environmental Compliance

 Due to the nature of our
products, we have incurred no costs with respect to environmental compliance with federal, state, and local laws. To our knowledge, our
products do not require governmental approval, and we do not foresee that governmental regulations will have a material impact on our
business.

 Employees

 As of June 30, 2025, we had
three full-time employees and had engaged several consultants and independent contractors over the past year. Members of our technical
team are comprised of experienced professionals who are chemists, civil, chemical, and mechanical engineers with expertise in hydrodynamic
cavitation, nano technology and water treatment. These individuals hold degrees in Civil, Chemical, and Mechanical Engineering.

 Research and Development Expenditures

 During the fiscal years ended
June 30, 2025 and 2024, we spent $95,000 and $61,000, respectively, on research and development activities.

 ITEM 1A. RISK FACTORS

 Not applicable for smaller reporting companies.

 ITEM 1B. UNRESOLVED STAFF COMMENTS

 None.

 ITEM 1C. CYBERSECURITY

 Risk

 The manner in which we store and/or transmit sensitive
data in connection with our research and development and our day-to-day operations. We recognize the importance of assessing, identifying,
and managing material risks associated with cybersecurity threats, as such term is defined in Item 106(a) of Regulation S-K. These risks
include, among other things: operational risks, intellectual property theft, fraud, extortion, harm to employees and violation of data
privacy or security laws.

 Identifying and assessing cybersecurity risk is integrated
into our overall risk management systems and processes. Cybersecurity risks related to our business, technical operations, privacy and
compliance issues are identified through review by our internal information technology governance, risk and compliance policies. To defend,
detect and respond to cybersecurity incidents, we, among other things: may conduct proactive privacy and cybersecurity reviews of systems
and applications, audit applicable data, conduct employee training, monitor emerging laws and regulations related to data protection and
information security and implement appropriate changes.

 Our risk management program also assesses third party
risks, and we perform third-party risk management to identify and mitigate risks from our vendors, suppliers, and other business partners
associated with our use of third-party service providers. Cybersecurity risks are evaluated when determining the selection and oversight
of applicable third-party service providers and potential fourth-party risks when handling and/or processing our employee, business or
customer data.

 ITEM 2. PROPERTIES

 Our corporate headquarter
is located in Chatsworth, California, with an area of approximately 5,000 square foot facility, which includes office space and an area
to conduct research and development. Our lease agreement for this property ended in February 2025. We continue leasing this property on
a month to month basis. Our monthly rent payments approximate $7,000. We do not anticipate any material difficulties in securing replacement
facilities on commercially reasonable terms, should the need arise.

 ITEM 3. LEGAL PROCEEDINGS

 The Company may be involved
in certain legal proceedings that arise from time to time in the ordinary course of its business. The Company records accruals for contingencies
to the extent that management concludes that the occurrence is probable and that the related amounts of loss can be reasonably estimated.
Legal expenses associated with the contingency are expensed as incurred.

 The Company is not aware
of any pending litigations.

 ITEM 4. MINE
SAFETY DISCLOSURES

 Not applicable.

 ITEM 5. MARKET
FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 Common Stock

 Our Common Stock is traded
on the OTCQB Market under the symbol CVAT.

 Holders

 As of September 26, 2025,
there were 1,031 holders of record of our common stock. This does not reflect the number of persons or entities who hold stock in nominee
or "street" name through various brokerage firms.

 Dividend Policy

 We have neither declared
nor paid any dividends on our Common Stock in the preceding two fiscal years. We currently intend to retain future earnings, if any, to
fund ongoing operations and finance the growth and development of our business and, therefore, do not anticipate declaring or paying cash
dividends on our Common Stock for the foreseeable future. Any future decision to declare or pay dividends will be at the discretion of
the Board of Directors and will be dependent upon our financial condition, results of operations, capital requirements, and such other
factors as the Board of Directors deems relevant.

 Issuance of unregistered
Securities

 None.

 Issuer Purchase of Equity
Securities

 None.

 ITEM 6. [RESERVED]

 ITEM 7. MANAGEMENT'S DISCUSSION
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 The following discussion
and analysis should be read in conjunction with our financial statements and the related notes. This discussion contains forward-looking
statements based upon current expectations that involve risks and uncertainties, such as its plans, objectives, expectations and intentions.
Actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements.

 Overview of Our Business

 We are a Nevada corporation
originally incorporated under the name Bio Energy, Inc. On January 29, 2007, we incorporated a wholly owned subsidiary, Hydrodynamic Technology,
Inc. as a California corporation.

 We have developed, patented,
and commercialized proprietary technology that can be used for processing of various industrial and consumer-oriented fluids, as discussed
in detail above.

30, 2025, we recorded revenue of $203,000 and a gain on the sale of our patents of $880,000 and incurred a net loss of $113,000.

 Inflation and potential
recession

 We are, and our suppliers
have experienced significant broad-based inflation of manufacturing and distribution costs as well as transportation challenges, partially
as a result of the pandemic and there is uncertainty over the impact that recently implemented tariffs on various countries will have
on the cost of our products or components used in our products. Although we do not believe that inflation has had a material effect on
our business, financial condition or results of operations, it may in the future. We are monitoring cost structures and evaluating to
what extent any such costs can be passed on to customers, taking into account the overall impact of increasing inflation and interest
rate pressures on consumers. We expect input cost inflation to continue at least throughout 2026. If we are unable to successfully manage
the effects of inflation, our business, operating results, cash flows and financial condition may be adversely affected. Additionally,
there have been various economic indicators that the United States economy may be entering a recession in upcoming quarters. An economic
recession could potentially impact the general business environment and the capital markets, which may have a material negative impact
on our financial results.

 Management's Plan
of Operation

 In October 2024, we assigned our patents relating
to vegetable oil refining to Desmet Belgium for gross proceeds of $880,000, however, we retained a worldwide, exclusive, transferable,
and royalty-free license to practice and use the Assigned Patents in the fields of water and wastewater processing, recovery, recycling,
and purification (including oilfield wastewater), as well as the manufacture, distillation, brewing, enhancement, sale, and marketing
of alcoholic beverages (the "Licensed Fields"), we also received a worldwide, exclusive, transferable, and royalty-free license
to practice and use the Assigned Patents and associated technical information, consistent with the scope of the Reserved License, and
additionally we retained exclusive rights to use the "Nano Reactor " mark for our businesses, systems, and products related
to the Licensed Fields.

 Under both the Reserved License and the Grant-Back
License, the Company will have a worldwide, exclusive, transferable, and royalty-free license and right to design, build, use, export,
improve, sell, and market Nano Reactor devices, as well as Nano Reactor systems and products that incorporate or utilize Nano
Reactor devices, limited to uses and applications within one or more of the Licensed Fields.

 As a result of this agreement, the Company expects
that Desmet will start to manufacture the Nano reactors by itself and sale of Nano reactors to Desmet by the Company will significantly
be reduced in future periods. We will continue to own and operate a large portfolio of patents and intellectual property rights
in applications not related to vegetable oil refining. The following are Management's plans going forward to generate revenues and
sustain the operations of the Company and its current status:

 1.

 Water Treatment and Remediation in the Permian Basin

 2.

 Water Remediation and Disinfection in Agriculture

 3.

 Business Venture with Alchemy Beverages, Inc.

 4.

 New Technologies: Hydro-Plasma

30, 2025, we generated a net loss of $113,000 after a gain from the assignment of our patents to Desmet of $880,000 and utilized cash
in our operations of $806,000. As of June 30, 2025, we have a working capital balance of $199,000 and a stockholders' equity of
$69,000.

 Management plans to generate
revenues in future from the commercial applications of the new technologies discussed above.

 Previously we generated revenues
from licensing fees and from the sale of reactors from our previous agreements with Desmet Belgium (previously Desmet Ballestra).

30, 2025, revenues recognized from sale of reactors amounted to $203,000. These funds are not sufficient to fund operational expenses
on monthly basis. We generated an additional $880,000 in the assignment of our patents to Desmet and anticipate that we will generate
revenues from the new technologies and additional markets identified above.

 There was no revenue produced
from our agreements with Enviro Watertek, LLC and Alchemy Beverages, Inc.

 We anticipate that we may
need additional funding, and we may attempt to raise additional debt and/or equity financing to fund operations and to provide additional
working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient amounts necessary to
meet our needs, or that we will be able to meet our future contractual obligations. Should management fail to obtain such financing, we
may curtail its operations.

 Critical Accounting Policies
and Revenue Recognition

 Our discussion and analysis
of our financial condition and results of operations are based upon our consolidated financial statements which have been prepared in
accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial
statements requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and
the reported amounts of revenues and expenses. The accounting policies and estimates described below are those we consider most critical
in preparing its consolidated financial statements. The following is a review of the accounting policies and estimates that include significant
judgments made by management using information available at the time the estimates are made. However, these estimates could change materially
if different information or assumptions were used instead.

 Note 1 of the accompanying
consolidated financial statements includes a summary of significant accounting policies, estimates, and methods used in the preparation
of our financial statements. Accounting estimates are an integral part of the preparation of financial statements and are based on judgments
by management using its knowledge and experience about the past and current events and assumptions regarding future events, all of which
we consider to be reasonable. These judgments and estimates reflect the effects of matters that are inherently uncertain and that affect
the carrying value of our assets and liabilities, the disclosure of contingent liabilities and reported amounts of expenses during the
reporting period.

 Revenue Recognition

 The Company follows the guidance
of Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers. ASC 606 creates a five-step model that
requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements
with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4)
allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is
satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration
it is entitled to in exchange for the services it transfers to its clients.

 Revenue from sale of our Nano
Reactor and LPN is recognized when products are shipped from our manufacturing facilities as this is
our sole performance obligation under these contracts and we have no continuing obligation to the customer.

 For the license fee
revenue, revenue is recognized when the Company satisfies the performance obligation based on the related license agreement.

 In addition, the Company
also recognizes revenues from usage fees of certain reactors. Usage fees are recognized based on actual usage by the customer.

 Leases

 The Company accounts for
leases under guidance of Accounting Standards Codification ("ASC") 842, which requires an entity to recognize a right-of-use
asset and a lease liability for virtually all leases. Leases with an initial term of 12 months or less are not recorded on the balance
sheet. The Company accounts for the lease and non-lease components of its office lease as a single lease component. Lease expense is recognized
on a straight-line basis over the lease term.

 Equity Method Investment

 The Company accounts for
investments in entities in which the Company has significant influence over the entity's financial and operating policies, but does
not control, using the equity method of accounting. The equity method investments are initially recorded at cost, and subsequently increased
for capital contributions and allocations of net income, and decreased for capital distributions and allocations of net loss. Equity in
net income (loss) from the equity method investment is allocated based on the Company's economic interest. The Company assesses
its investment in equity method investments for recoverability, and if it is determined that a loss in value of the investment is other
than temporary, the Company writes down the investment to its fair value. Based on Management's assessment, the value of its equity
method investment was impaired as of June 30, 2023 and as such, recorded an impairment charge of $1,112,000. As of June 30, 2025 and 2024,
the remaining value of its investments amounted to a de minimus amount of $1,000, respectively.

 Share-Based Compensation

 The Company periodically
issues stock options and warrants to employees and non-employees in non-capital raising transactions for services and for financing costs.
The Company accounts for stock option and warrant grants issued and vesting to employees based on the authoritative guidance provided
by the Financial Accounting Standards Board whereas the value of the award is measured on the date of grant and recognized over the vesting
period. The Company accounts for stock option and warrant grants issued and vesting to non- employees in accordance with the authoritative
guidance of the Financial Accounting Standards Board whereas the value of the stock compensation is based upon the measurement date as
determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to
earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period
on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants
are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.

 Recent Accounting Pronouncements

 See Note 1 of the financial
statements for discussion of recent accounting pronouncements.

 Results of Operations

 Below is summary comparing
fiscal 2025 and fiscal 2024.

 For the Years Ended

 2025

 2024

 $ Change

 % Change

 Revenue

 $
 203,000

 $
 1,363,000

 $
 (1,160,000
)

 (85.1
)

 Cost of revenue

 (38,000
)

 (156,000
)

 118,000

 (75.6
)

 Gross profit

 165,000

 1,207,000

 (1,042,000
)

 (86.3
)

 General and administrative expenses

 1,057,000

 708,000

 349,000

 49.3

 Research and development expenses

 95,000

 61,000

 34,000

 55.7

 Total operating expenses

 1,152,000

 769,000

 383,000

 49.8

 Income (loss) from operations

 (987,000
)

 438,000

 (1,425,000
)

 325.3

 –

 100.0

 Interest and other income (expense), net

 (6,000
)

 1,000

 (7,000
)

 (700.0
)

 Net income (loss)

 $
 (113,000
)

 $

 $
 (552,000
)

 (125.7
)

 Revenue

 During the year ended
June 30, 2025, revenue decreased by $1,160,000, as a result of the decrease in reactors purchased by Desmet, prior to the assignment
of the patents to Desmet, which resulted in a decrease in revenues from reactor sales from $865,000 to $198,000 and a fee of $5,000 from
the use of a reactor by a new customer. In addition, the Company also recognized $498,000 of license fee in 2024 pursuant to the termination
of the October 2021 agreement with Desmet. There was no similar license fee revenue in fiscal 2025.

 Cost of Sales

30, 2025 and 2024, cost of sales was $38,000 and $156,000, respectively, a decrease of $118,000 or 76.0%. The decrease is directly attributable
to the cost of the production of reactors which corresponds to the decrease in reactors revenues. In addition, in the prior year, the
Company recognized license fee revenue of $498,000, with no associated cost of sales. After taking these items into account the cost of
sales movement is in line with normal margins earned.

 General and administrative
expenses

 General and administrative
expenses increased by $349,000 or 49.0%. The Increase is primarily attributable to the following:

 Payroll expenses increased by $121,000 due to the employment of a previous officer of the Company to assist
with product development,

 Stock based compensation increased by $201,000 due to stock purchase warrants granted to certain of the
Company's employees and consultants and common stock issued to consultants for services rendered,

 Legal fees increased by $43,000 due to patent activity and the expenses incurred with the assignment of
patents to Desmet.

 Travel expenses decreased by $20,000 due to a reduction in travel by our officers during the current year.

 Research and development
expenses

 Research and development
expenses increased by $34,000. During the current year, as in the prior year, management continued investing in research into cold plasma
technology to be applied to new markets.

was $880,000 for the year ended June 30, 2025 as a result of sale and assignment of certain patents to Desmet in October 2024. There was
no similar transaction during the prior period.

 Interest and other income
(expense), net

 Interest and other
income (expense) increased by $7,000, this is primarily due to interest on the SBA loan. In the prior year an adjustment was made to
the accrued interest on the SBA loan after reconciling to the balance reflected by the SBA noteholder.

 Net Loss

 Our net loss in fiscal 2025
was $113,000 and our net income in fiscal 2024 was $439,000, an increase in loss of $552,000 due primarily to a decrease in revenue, an
increase in general and administrative expenses and research and development costs, offset by the gain realized on the patent assignment,
discussed above.

 Liquidity and Capital
Resources

 Our cash balance at June
30, 2025 and 2024 was $249,000 and $179,000, respectively, an increase of $70,000, primarily due to the proceeds realized on the assignment
of patents to Desmet during October 2024.

 We utilized cash of $806,000
to fund operating activities, due to a reduction in revenues and the increase in operating expenses discussed above.

 We generated cash of $880,000
from the assignment of our patents to Desmet.

 We utilized cash in financing
activities of $4,000 for the year ended June 30, 2025, for the installment payment of notes payable.

 Going concern

30, 2025, the Company incurred net loss of $113,000 and used cash in operations of $806,000 and as of June 30, 2025, we had
an accumulated deficit of $26,960,000. The Company has had a history of operating losses. These factors, among others, raise substantial
doubt about our ability to continue as a going concern within one year of the date that the financial statements are issued. In addition,
the Company's independent registered public accounting firm, in its report on our June 30, 2025 financial statements, has raised
substantial doubt about the Company's ability to continue as a going concern. The Company's financial statements do not include
any adjustments that might result from the outcome of this uncertainty be necessary should we be unable to continue as a going concern.

 Management's plan is
to generate income from the application of new technologies as discussed above.

 We may also attempt to raise
additional debt and/or equity financing to fund operations and to provide additional working capital. There is no assurance that such
financing will be available in the future or obtained in sufficient amounts necessary to meet our needs, that we will be able to achieve
profitable operations or that we will be able to meet our future contractual obligations. Should management fail to obtain such financing,
the Company may curtail its operations.

 Off-balance Sheet Arrangements

 We have no off-balance sheet
arrangements that have or are reasonably likely to have a current or future effect on its financial condition, revenues or expenses, results
of operations, liquidity, capital expenditures or capital resources.

 ITEM 7A. QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 Not applicable for Smaller
Reporting Companies.

 ITEM 8. FINANCIAL STATEMENTS AND
SUPPLEMENTARY DATA

 Page

 Report of the Independent, Registered Public Accounting firm PCAOB # 572

 Consolidated Balance Sheets as of June 30, 2025 and June 30, 2024

 Consolidated Statements of Operations for the years ended June 30, 2025 and June 30, 2024

 Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the years ended June 30, 2025 and 2024

 Consolidated Statements of Cash Flows for the years ended June 30, 2025 and 2024

 Notes to the Consolidated Financial Statements

 REPORT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM

 To the Stockholders and Board of Directors

Cavitation Technologies, Inc.

 Chatsworth, CA

 Opinion on the Consolidated
Financial Statements

 We have audited the accompanying
consolidated balance sheets of Cavitation Technologies, Inc. (the "Company") as of June 30, 2025 and 2024, the related consolidated
statements of operations, changes in stockholders' equity (deficit), and cash flows for the years then ended, and the related notes
(collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements
present fairly, in all material respects, the financial position of the Company as of June 30, 2025 and 2024, and the results of their
operations and their cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States
of America.

 Going Concern

 The accompanying consolidated
financial statements have been prepared assuming that the Company will continue as a going concern. During the year ended June 30, 2025,
the Company incurred a net loss and used cash in operations. In addition, the Company has a history of reporting net losses and negative
operating cash flows. These matters raise substantial doubt about the Company's ability to continue as a going concern. Management's
plans in regard to these matters are also described in Note 1 to the financial statements. These consolidated financial statements do
not include any adjustments that might result from the outcome of this uncertainty.

 Basis for Opinion

 These consolidated financial
statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's
consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S.
federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 We conducted our audits in
accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not
required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we
are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

 Our audits included performing
procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for
our opinion.

 Critical Audit Matter

 Critical audit matters are
matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the
audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially
challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

 We have served as the Company's
auditor since 2013.

 /s/ Weinberg & Company, P.A.

 Los Angeles, California

INC.

CONSOLIDATED BALANCE SHEETS

 June 30, 2025

 June 30, 2024

 ASSETS

 Current assets:

 Cash and cash equivalents

 $
 249,000

 $
 179,000

 Accounts receivable

 –

 Prepaid expenses

 27,000

 16,000

 Total current assets

 286,000

 195,000

 Equity method investment

 1,000

 1,000

 Operating lease right-of-use asset

 –

 42,000

 Other assets

 Total assets

 $
 297,000

 $
 248,000

 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

 Current liabilities:

 Accounts payable and accrued expenses

 $
 93,000

 $
 129,000

 Accrued payroll and payroll taxes – related parties

 –

 414,000

 Notes payable

 9,000

 9,000

 Operating lease liability, current portion

 –

 46,000

 Total current liabilities

 102,000

 598,000

 Notes payable, non-current

 126,000

 130,000

 Total liabilities

 228,000

 728,000

 Commitments and contingencies

 –

 –

 Stockholders' equity (deficit):

 Preferred stock, $ 0.001 par
 value, 10,000,000
 shares authorized, no
 shares issued and outstanding as of June 30, 2025 and 2024

 –

 –

 Common stock, $ 0.001 par
 value, 1,000,000,000
 shares authorized, 289,156,340
 and 284,289,740
 shares issued and outstanding as June 30, 2025 and 2024

 289,000

 284,000

 Additional paid-in capital

 26,740,000

 26,083,000

 Accumulated deficit

 ( 26,960,000
)

 ( 26,847,000
)

 Total stockholders' equity (deficit)

 69,000

 ( 480,000
)

 Total liabilities and stockholders' equity (deficit)

 $
 297,000

 $
 248,000

 See accompanying notes to
the consolidated financial statements

INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

 For the Years Ended

 2025

 2024

 Revenue – Nano reactors

 $
 203,000

 $
 865,000

 Revenue – license fee

 –

 498,000

 Total revenue

 203,000

 1,363,000

 Cost of revenue

 ( 38,000
)

 ( 156,000
)

 Gross profit

 165,000

 1,207,000

 General and administrative expenses

 1,057,000

 708,000

 Research and development expenses

 95,000

 61,000

 Total operating expenses

 1,152,000

 769,000

 Income (loss) from operations

 ( 987,000
)

 438,000

 Other Income (Expense)

 –

 Interest and other income (expense), net

 ( 6,000
)

 1,000

 Net income (loss)

 $
)

 $

 Net income (loss) per share

 Basic and diluted

 $
 ( 0.00
)

 $
 0.00

 Weighted average shares outstanding,

 Basic and diluted

 286,001,131

 284,289,740

 See accompanying notes to
the consolidated financial statements

INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)

 YEARS ENDED JUNE 30, 2025
AND 2024

 Common
 Stock

 Additional
 Paid-in

 Accumulated

 Shares

 Amount

 Capital

 Deficit

 Total

 Balance at June 30, 2023

 284,289,740

 $
 284,000

 $
 26,083,000

 $
 ( 27,286,000
)

 $
 ( 919,000
)

 Net income

 –

 –

 –

 Balance at June 30, 2024

 284,289,740

 284,000

 26,083,000

 ( 26,847,000
)

 ( 480,000
)

 Fair value of common stock issued
 for services

 200,000

 –

 6,000

 –

 6,000

 Fair value of common stock issued
 to settle accrued payroll and payroll taxes – related parties

 4,666,600

 5,000

 85,000

 –

 90,000

 Fair value of warrants granted
 for services

 –

 –

 195,000

 –

 195,000

 Fair value of warrants issued to
 settle accrued payroll and payroll taxes – related parties

 –

 –

 100,000

 –

 100,000

 Extinguishment of accrued payroll
 and payroll taxes – related parties treated as contribution of capital

 –

 –

 271,000

 –

 271,000

 Net loss

 –

 –

 –

)

)

 Balance at June 30, 2025

 289,156,340

 $
 289,000

 $
 26,740,000

 $
 ( 26,960,000
)

 $
 69,000

 See accompanying notes to
the consolidated financial statements

INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

 Years Ended June 30,

 2025

 2024

 Operating activities:

 Net income (loss)

 $
)

 $

 Adjustments to reconcile net income (loss) to net cash generated by (used in) operating activities:

 Depreciation

 –

 1,000

 Fair value of warrants granted for services

 195,000

 –

 Fair value of common stock issued for services

 6,000

 –

 ( 880,000
)

 –

 Effect of changes in:

 Accounts receivable

 ( 10,000
)

 –

 Prepaid expenses

 ( 11,000
)

 ( 16,000
)

 Operating lease right-of-use assets

 42,000

 71,000

 Accounts payable and accrued expenses

 –

 9,000

 Accrued payroll and payroll taxes – related parties

 11,000

 134,000

 Customer advances

 –

 ( 391,000
)

 Operating lease liabilities

 ( 46,000
)

 ( 75,000
)

 Net cash generated by (used in) operating activities

 ( 806,000
)

 172,000

 Investing activities:

 Proceeds from patent assignment

 –

 Net cash provided by investing activities

 –

 Financing activities:

 Repayment of notes payable

 ( 4,000
)

 ( 11,000
)

 Cash used in financing activities

 ( 4,000
)

 ( 11,000
)

 Net increase in cash and cash equivalents

 70,000

 161,000

 Cash and cash equivalents, beginning of period

 179,000

 18,000

 Cash and cash equivalents, end of period

 $
 249,000

 $
 179,000

 Supplemental disclosures of cash flow information:

 Cash paid for interest

 $
 6,000

 $
 –

 Cash paid for income taxes

 $
 –

 $
 –

 Non-Cash Investing and Financing Activities

 Fair value of common stock issued to settle accrued payroll and payroll taxes – related parties

 $
 90,000

 $
 –

 Fair value of warrants issued to settle accrued payroll and payroll taxes – related parties

 $
 100,000

 $
 –

 Extinguishment of accrued payroll and payroll taxes – related parties treated as contribution of capital

 $
 271,000

 $
 –

 See accompanying notes to
the consolidated financial statements

INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2025 AND 2024

 Note 1 – Organization
and Summary of Significant Accounting Policies

 Cavitation Technologies,
Inc. ("the Company," "CTi," "we," "us," and "our") is a Nevada corporation
originally incorporated in January 2007 under the name Bio Energy, Inc. The Company has developed, patented, and commercialized proprietary
technology used in our Nano Reactor and LPN liquid processing applications.

 Patent assignment and license back agreement

 On October 9, 2024, the Company has entered into an
agreement with Desmet that monetized the Company by the assignment of certain of its U.S. and non-U.S. patents, technical information
and related intellectual property (the "Assigned Patents") that for several years have been licensed to Desmet for its use
on a global basis in vegetable oil, fats and oleo applications (see Note 2).

 Going Concern

 The accompanying consolidated financial statements
have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments
in the normal course of business. As reflected in accompanying consolidated financial statements, during the year ended June 30, 2025,
the Company incurred net loss of $ 113,000, used cash in operations of $ 806,000 and as of June 30, 2025, the Company had an accumulated
deficit of $ 26,960,000. In addition, the Company has had a history of operating losses. These factors, among others, raise substantial
doubt about the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include
any adjustments that may result from an inability of the Company to continue as a going concern.

 As of June 30,
2025, the Company has cash in the amount of $ 249,000. The Company's ability to continue as a going concern is dependent upon its
ability to continue to implement its business plan. Currently, management's plan is to increase revenues by continuing to license
its technology globally. While the Company believes in the viability of its strategy to increase revenues, there can be no assurances
to that effect. The Company believes it has enough cash to sustain operations through December, 2025.

may also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. There
is no assurance that such financing will be available in the future or obtained in sufficient amounts necessary to meet the Company's
needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual
obligations. Should management fail to obtain such financing, the Company may curtail its operations.

 Principles of Consolidation

 The consolidated financial statements include the
accounts of Cavitation Technologies, Inc. and its wholly owned subsidiary Hydrodynamic Technology, Inc. Intercompany transactions and
balances have been eliminated in consolidation.

 Use of Estimates

 The preparation
of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to
make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities
at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates include
valuation of our equity method investments, assumptions used in valuing our stock options, stock warrants and common stock issued for
services and valuation allowance for our deferred tax asset, among other items. Actual results could differ from these estimates.

 Revenue Recognition

follows the guidance of Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC")
606, Revenue from Contracts with Customers ("ASC 606"). ASC 606 creates a five-step model that requires entities to exercise
judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying
our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price
to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies
the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for
the services it transfers to its clients. Revenue from sale of our Nano Reactors is recognized when products are shipped from our manufacturing
facilities as this is our sole performance obligation under these contracts and we have no continuing obligation to the customer.

 For the license fee revenue, revenue is recognized
when the Company satisfies the performance obligation based on the related license agreement and
collectability is certain.

 In addition,
the Company also recognizes revenues from usage fees of certain reactors. Usage fees are recognized based on actual usage by the customer
and collectability is certain.

 Cash and
Cash Equivalents

 The Company considers highly liquid
investments with original maturities of three months or less to be cash equivalents. At June 30, 2025 and 2024, the Company had no
cash equivalents.

maintains its cash with one domestic financial institution. From time to time, cash balances in this domestic bank may exceed federally
insured limits provided by the Federal Deposit Insurance Corporation ("FDIC") of up to $250,000.

 As of June 30,
2025, Company had no deposits in excess of federally insured limit. The Company believes that no significant concentration
of credit risk exists with respect to this cash balances because of its assessment of the creditworthiness and financial viability of
this financial institution.

 Equity Method Investment

accounts for investments in entities in which the Company has significant influence over the entity's financial and operating policies,
but does not control, using the equity method of accounting. The equity method investments are initially recorded at cost, and subsequently
increased for capital contributions and allocations of net income, and decreased for capital distributions and allocations of net loss.
Equity in net income (loss) from the equity method investment is allocated based on the Company's economic interest. Equity method
investments are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.
If it is determined that a loss in value of the equity method investment is other than temporary, an impairment loss is measured based
on the excess of the carrying amount of an investment over its estimated fair value. Impairment analyses are based on current plans, intended
holding periods, and available information at the time the analysis is prepared. As of June 30, 2025 and 2024, the remaining de minimus
value of its investments was $ 1,000, respectively.

 Income Taxes

 The Company follows the asset and liability method
of accounting for income taxes. The Company recognizes deferred tax assets and liabilities to reflect the estimated future tax effects,
calculated at anticipated future tax rates, of future deductible or taxable amounts attributable to events that have been recognized on
a cumulative basis in the financial statements. A valuation allowance related to a deferred tax asset is recorded when it is more likely
than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects
of the changes in tax laws and rates of the date of enactment.

 Leases

accounts for its leases in accordance with the guidance of FASB ASC 842, Leases. The Company determines whether a contract is, or contains,
a lease at inception. Right-of-use assets represent the Company's right to use an underlying asset during the lease term, and lease
liabilities represent the Company's obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities
are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company
uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid
lease payments (see Note 4). Leases with an initial term of 12 months or less are not recorded on the balance sheet.

 Share-Based
Compensation

 We periodically
issue stock options, warrants and common stock to employees and non-employees for services and capital raising transactions. We account
for share-based payments under the guidance of FASB ASC 718, which requires the measurement and recognition of compensation expense for
all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated
fair values. We estimate the fair value of stock option and warrant awards to employees and directors on the date of grant using an option-pricing
model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service
period in our Statements of Operations. We estimate the fair value of restricted stock awards to employees and directors using the market
price of our common stock on the date of grant, and the value of the portion of the award that is ultimately expected to vest is recognized
as expense over the required service period in our Statements of Operations. Recognition of compensation expense for non-employees is
in the same period and manner as if the Company had paid cash for the services.

 Fair Value Measurement

 FASB ASC 820-10 requires entities to disclose the
fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable
to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged
in a current transaction between willing parties.

 In addition to defining fair value, the standard expands
the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the
inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value
measurement is reported in one of the three levels which are determined by the lowest level input that is significant to the fair value
measurement in its entirety. These levels are:

 Level 1 - inputs are based upon unadjusted quoted
prices for identical instruments traded in active markets.

 Level 2 - inputs are based upon significant observable
inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not
active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated
by observable market data for substantially the full term of the assets or liabilities.

 Level 3 - inputs are generally unobservable and typically
reflect management's estimates of assumptions that market participants would use in pricing the asset or liability. The fair values
are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.

 As of June 30,
2025, and 2024, the carrying value of certain accounts such as accounts receivable, accounts payable, accrued expenses and accrued payroll
approximates their fair value due to the short-term nature of such instruments. The carrying value of our note payable approximate their
fair value due to interest rate of the note.

 Advertising Costs

 Advertising costs, including marketing expense, incurred
in the normal course of operations are expensed as incurred. Advertising expenses amounted to $ 16,000 and $ 9,000 for the years
ended June 30, 2025 and 2024 respectively and was reported as part of General and administrative expenses in the accompanying Consolidated
Statements of Operations.

 Research and Development Costs

 Research and
development expenses relate primarily to the development, design, testing of preproduction prototypes and models, compensation, and consulting
fees related to the Company's cold plasma technology, and are expensed as incurred. Total research and development costs recorded
during the years ended June 30, 2025 and 2024 amounted to $ 95,000 and $ 61,000, respectively.

 Warranty Policy

 The Company provides a limited warranty with every
set of reactors sold, typically 2 to 5 years. The Company has not experienced significant claims under its warranty policy, and management
determined no accrual for warranty reserve was necessary at June 30, 2025 and 2024.

 Net Income (Loss) Per Share

 The Company's
computation of net income (loss) per share ("EPS") includes basic and diluted EPS. Basic EPS is measured as the income available
to common stockholders divided by the weighted average common shares outstanding for the period. Diluted income per share reflects the
potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised
or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company as if they had
been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted income per share, the treasury
stock method assumes that outstanding options and warrants were exercised and the proceeds are used to purchase common stock at the average
market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average
market price of the common stock during the period exceeds the exercise price of the options and warrants. Potential common shares that
have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation
of diluted EPS.

 There were no
adjustments to net income (loss) required for purposes of computing diluted earnings per share. At June 30, 2025 and 2024 the Company
excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation
of its diluted earnings per share, as their effect would have been anti-dilutive as the exercise price of these warrants were greater
than the stock price of the Company common stock.

 Schedule of anti-dilutive shares

 June 30, 2025

 June 30, 2024

 Warrants

 49,041,323

 28,841,323

 Concentrations

 During the year ended June 30, 2025 and 2024, we recorded 98 %
of our revenue from Desmet Belgium (Desmet) (see Note 2).

 As of June 30, 2025, two vendors accounted for
 18 % and 7 % of the Company's accounts payable. As of June 30, 2024, three vendors accounted 19 %, 15 % and 11 % of the
Company's accounts payable.

 At June 30, 2025, we had receivables of $ 10,000
from one customer.

 Segments

operates in one segment for the development and distribution of our products. In accordance with the "Segment Reporting" Topic
of the ASC, the Company's chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating
results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based
on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report
annually entity-wide disclosures about products and services and major customers. All material operating units qualify for aggregation
under "Segment Reporting" due to their similar customer base, single sales team, marketing department, customer service department,
operations department, finance and accounting department to support its operations and similarities in economic characteristics; nature
of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial
information required by "Segment Reporting" can be found in the accompanying financial statements.

 Inflation

 The continuing impact of higher inflation, impacted
by the uncertainty of the implementation of recent tariffs and the actions by the Federal Reserve to address inflation, create uncertainty
about the future economic environment which will continue to evolve and, we believe, has not materially impacted the Company's business
in fiscal 2025. The implications of higher government deficits and debt, tighter monetary policy, implemented tariffs and potentially
higher long-term interest rates may drive a higher cost of capital for the business and an increase in the Company's operating expenses.

 Recent Accounting Pronouncements

 In November 2024, the FASB issued ASU 2024-03, Income
Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,
requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements
on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning
after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03.

 Other recent accounting pronouncements issued by the
FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange
Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial
statements.

 Note 2 – Contracts with Desmet Ballestra

 In October 2021, the Company signed a three-year global
Research and Development, Marketing and Technology License Agreement ("TLA") with Desmet Ballestra ("Desmet")
for the sale and licensing of the Company's nano reactors. This agreement was a continuation of the similar TLA agreements the Company
signed with Desmet in fiscals 2012, 2016 and 2018.

 On
February 15, 2024, Desmet and the Company terminated the October 2021 TLA agreement and entered into a new three-year Technology
License Agreement ("February 2024 TLA"). The February 2024 TLA provides for a worldwide limited exclusive license to
market, sell, supply and assistance to customers of Nano reactor systems and nano reactor devices for the treatment of certain oil
and fats, oleochemicals, biodiesels, fatty acids and fatty alcohols. The February 2024 TLA may be terminated by Desmet on March 15
each year on at least one month's written notice if the licensee and its affiliates failed to sell a minimum of 6 nano reactor
systems during the preceding 12 month period. As part of the February 2024 TLA, Desmet also agreed to provide advances of $25,000
per month, subject to limitations. The advances will then be applied as payment against future sales of reactors to Desmet. In
addition, Desmet also waived its right to collect certain outstanding advances of $498,000 during the year ended June 30, 2024 that
were received and recorded under the October 2021 TLA agreement. As a result, the Company recognized licensing revenue of $ 498,000 to
account for the extinguishment of these advances. As the TLA is the principal agreement between the Company and Desmet and the basis
for revenue recognition, the Company has determined that the inherent characteristics of the waiver of the $498,000 are revenue
related.

 On October 9, 2024, the Company executed a Patent
Assignment and License Back Agreement with Desmet with regards to the patents and intellectual property used in the production of reactors
sold to Desmet. This agreement superseded certain terms of the February 2024 TLA, including, the termination of $25,000 monthly advances
the Company used to receive from Desmet.

 During the year ended June 30, 2025 and 2024,
pursuant to these TLA agreements, the Company recognized revenues from sale of Nano Reactors to Desmet totaling $ 198,000
and $ 865,000,
respectively.

 Patent Assignment and License Back Agreement

 On October 9, 2024, as disclosed in Note 1 above,
the Company entered into a patent assignment and license back agreement with Desmet, whereby the Company assigned certain of its U.S.
and non-U.S. patents, technical information and related intellectual property (the "Assigned Patents") that for several years
have been licensed to Desmet for its use on a global basis in vegetable oil, fats and oleo applications, effectively terminating the February
2024 TLA Agreement.

 The Company also assigned to Desmet, ownership of
two U.S. trademark registrations that it holds for its Nano Neutralization and Nano Reactor marks, respectively (the "Assigned
Marks"). The consideration for the assignment of the patents amounted to $ 880,000, which was collected in full. The Company has
also agreed to provide to Desmet any consultation, technical assistance and support services that Desmet may reasonably request in; (a)
installing, operating or troubleshooting for any Nano Reactor Device; (b) testing, startup or maintenance of any Nano Reactor
Device or any problems associated therewith; and (c) providing training to representatives, contractors or employees of Desmet or any
Site User, to be charged at a rate of $1,000 per day, plus reimbursement of reasonable expenses.

 Pursuant to the patent assignment and license back
agreement, the Company reserved for itself, and received a Grant Back License ("Reserved Grant Back License") of a worldwide,
exclusive, transferable and royalty-free license and right to practice and use the Assigned Patents and associated technical information
in businesses, activities, projects, uses and applications in the field of; (i) water and wastewater processing, recovery, recycling and
purification (including oilfield wastewater) and; (ii) manufacture, distillation, brewing, enhancements, sale and marketing of alcoholic
beverages, together the Licensed Fields (the "Licensed Fields"). Under the Reserved Grant Back License retained and received,
the Company will have a worldwide, exclusive, transferable and royalty-free license and right to design, build, use, export, improve,
sell and market Nano Reactor devices and Nano Reactor devices and systems (and products) that incorporate or utilize Nano Reactor
devices, in each case within the Licensed Fields, and to continue to use the Nano Reactor trademark in connection with its business,
systems and products within the Licensed Fields.

 The Company has expensed costs associated with these
patents in prior years and had no carrying value upon closing of this transaction. The Company followed the guidance of ASC 610, Other
Income, to account for this transaction. As a result, the Company recognized the entire $ 880,000 as Gain on Patent Assignment in
the accompanying statement of operations.

 Note 3 – Segment Information

 The Company operates and manages its business as one
reportable and operating segment. The Company's CODM reviews financial information presented and decides how to allocate resources
based on net income (loss). Net income (loss) is used for evaluating financial performance.

 Significant segment expenses include research
and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to
operate the business, which primarily include external professional services and other administrative expenses. The following
table presents the significant segment expenses and other segment items regularly reviewed by our CODM:

 Schedule of segment information

 Year Ended December 31,

 2025

 2024

 Revenue

 $
 203,000

 $
 1,363,000

 Cost of revenue

 ( 38,000
)

 ( 156,000
)

 Gross profit

 165,000

 1,207,000

 Research and development

 ( 95,000
)

 ( 61,000
)

 Salaries

 ( 471,000
)

 ( 351,000
)

 Consulting fees

 ( 67,000
)

 ( 34,000
)

 Professional fees

 ( 168,000
)

 ( 140,000
)

 Rent expense

 ( 29,000
)

 ( 55,000
)

 Travel expense

 ( 30,000
)

 ( 50,000
)

 Stock-based compensation

 ( 200,000
)

 –

 Other operating expenses

 ( 92,000
)

 ( 78,000
)

 Total operating expenses

 ( 1,152,000
)

 ( 769,000
)

 –

 Interest expense

 ( 6,000
)

 1,000

 Net Income (loss)

 $
)

 $

 Note 4 – Operating
Lease

leased certain warehouse and corporate office space under an operating lease agreement. We determined if the arrangement is a lease at
inception. Lease assets are presented as operating lease right-of-use assets and the related liabilities are presented as lease liabilities
in our consolidated balance sheets. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The
operating lease agreement for the warehouse and corporate office space expired in January 2025 and now operates as a month to month lease,
accordingly the Company no longer records a right of use asset or operating lease liability.

 Operating lease
right-of-use ("ROU") assets and liabilities are recognized at commencement date based on the present value of lease payments
over the lease term. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our
obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in lease arrangements is not readily
determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The Company's
incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be. The operating lease ROU
asset includes any lease payments made and excludes lease incentives.

 The components
of lease expense and supplemental cash flow information related to leases for the period are as follows:

 Schedule of components
of lease expense and supplemental cash flow information related to leases

 2025

 2024

 Lease costs:

 Operating lease (included in general and administrative in the Company's consolidated statement of operations)

 $
 80,000

 $
 76,000

 Other information:

 Cash paid for amounts included in the measurement of lease liabilities

 $
 84,000

 $
 78,000

 Weighted average remaining lease term – operating leases (in years)

 –

 0.6

 Average discount rate – operating leases

 –

 4 %

 The supplemental balance sheet information
 related to leases for the period is as follows:

 Long-term right-of-use assets

 $
 –

 $
 42,000

 Short-term operating lease liabilities

 $
 –

 $
 46,000

 Long-term operating lease liabilities

 –

 –

 Total operating lease liabilities

 $
 –

 $
 46,000

 In January 2025, the lease agreement expired and is
currently on a month to month basis.

 Note 5 – Related Party
Transactions

 Accrued Payroll and Payroll Taxes

 The Company accrues salaries and estimated payroll
taxes due to a former officer and current shareholder and current officer and director of the Company. As of June 30, 2024, the total
accrued payroll and payroll related taxes amounted to $ 414,000.

 During the year ended June 30, 2025, the Company accrued
an additional $ 11,000 in payroll.

 In February 2025, the Company settled with these
former officer and current officer to extinguish the accrued payroll and payroll related taxes amounting to $425,000 and unpaid
health insurance and cellphone reimbursements recorded in prior years totaling $36,000 for a total liability of $461,000. As part of
the settlement, the Company issued 4,666,600
shares of common stock with a fair value of $ 90,000
and warrants to purchase 5,000,000
shares of common stock. The warrants are fully vested, exercisable at $ 0.016
per share and will expire in five years. The estimated fair value of these warrants amounted to $ 100,000 using
the Black Scholes Option Pricing Model using the following inputs (i) stock price at the date of grant of $0.020; (ii) risk free
interest rate of 4.37% based on rates established by the Federal Reserve Bank; (iii) expected volatility 290% based on historical
volatility of the Company's common stock commensurate with the expected life of the warrants; (iv) expected life of 5 years
based on the contractual life; and (v) dividend yield of 0% based on no dividends paid or expected to be paid.

 Pursuant to current accounting and SEC
guidelines and regulations with regards to related party transactions, the Company accounted for the difference of $271,000 between
the carrying amount of the accrued payroll and other liability of $461,000 and the fair value of the common stock and warrants
issued of $ 190,000 as capital contribution.

 Consulting Fees

 The Company recognized consulting fees to a
member of the Company's Board of Directors amounting to $ 5,000
and $ 8,000
for the years ended June 30, 2025 and 2024, respectively.

 Note 6 – Note Payable

 Schedule of notes payable

 2025

 2024

 Note payable - EIDL

 $
 135,000

 $
 139,000

 Disclosed as:

 Short-term note payable

 9,000

 9,000

 Long-term note payable

 126,000

 130,000

 Total note payable

 $
 135,000

 $
 139,000

 In July 2020, the Company received a loan of
$ 150,000 from the SBA under its Economic Injury Disaster Loan (EIDL) assistance program. The EIDL loan is payable over 30 years,
bears interest at a rate of 3.75 % per annum and secured by all tangible and intangible property of the Company. As of June 30, 2025
and 2024, the outstanding balance of the note payable was $ 135,000 and $ 139,000, respectively.

 The expected future principal payment of note payable
June 30, 2025, is as follows:

 Schedule of future minimum payments on note payable

 Year Ending

 Amount

 June 30, 2026

 $
 9,000

 June 30, 2027

 9,000

 June 30, 2028

 9,000

 June 30, 2029

 9,000

 June 30, 2030 and thereafter

 99,000

 Total

 $
 135,000

 Note 7 - Stockholders'
Deficit

 Preferred Stock

 On March 17,
2009, the Company filed an Amended and Restated Articles of Incorporation and created two new series of preferred stock, the first of
which is designated Series A Preferred Stock and the second of which is designated as Series B Preferred Stock. The total number of shares
of Common Stock which this corporation has authority to issue is 1,000,000,000 shares of Common Stock and 10,000,000 shares of Preferred
Stock of which 5,000,000 shares are designated as Series A Preferred Stock, and 5,000,000 shares are designated as Series B Preferred
Stock, with the rights, preferences and privileges of the Series B Preferred Stock to be designated by the Board of Directors. Each share
of Common Stock and Preferred Stock has a par value of $0.001. As of June 30, 2025, and 2024, there are no shares of Series A or Series
B Preferred Stock issued and outstanding.

 Common Stock

 Year Ending June 30, 2025

 In February 2025, the Company issued 4,666,600
shares of common stock with a fair value of $ 90,000
to settle accrued payroll and payroll taxes – related party (see Note 5).

 On June 10, 2025, the Company issued 200,000
shares of common stock with a fair value of $ 6,000
for consulting services.

 Year Ending June 30, 2024

 There was no
common stock issued for the year ended June 30, 2024.

 Stock Options

 The Company has not adopted a
formal stock option plan and does no t
have any stock options issued and outstanding as of and during the years ended June 30, 2025 and 2024.

 Warrants

 Year ended June 30, 2025

 In November 2024 and February 2025 the
Company granted 5 year warrants exercisable for 15,200,000
shares of common stock at an exercise prices ranging from $ 0.013
to $ 0.017
per share to employees and certain consultants for services rendered. The estimated fair value amounted to $ 195,000
and was derived using the Black Scholes Option Pricing Model using the following inputs (i) stock price at the date of grant ranging
from $0.010 to $0.020; (ii) risk free interest rate of 4.24% to 4.37% based on rates established by the Federal Reserve Bank; (iii)
expected volatility 283% to 290% based on historical volatility of the Company's common stock commensurate with the expected
life of the warrants; (iv) expected life of 5 years based on the contractual life; and (v) dividend yield of 0% based on no
dividends paid or expected to be paid.

 In February 2025, the Company issued warrants
to purchase 5,000,000 shares of common stock with an estimated fair value of $ 100,000 to settle accrued payroll – related party (see Note 5).

 A summary of the Company's
warrant activity and related information from as of June 30, 2025 and 2024 is as follows.

 Schedule of warrant activity

 Warrants

 Weighted-
 Exercise
 Price

 Weighted-
 Remaining
 Contractual
 Life
 (Years)

 Outstanding at June 30, 2023

 53,657,234

 $
 0.090

 2.18

 - Granted

 –

 –

 –

 - Exercised

 –

 –

 –

 - Expired

 ( 24,815,911
)

 –

 –

 Outstanding at June 30, 2024

 28,841,323

 $
 0.080

 2.61

 - Granted

 20,200,000

 0.015

 4.76

 - Exercised

 –

 –

 –

 - Expired

 –

 –

 –

 Outstanding at June 30, 2025

 49,041,323

 $
 0.053

 2.81

 As of June 30, 2025, the intrinsic
value of these stock purchase warrants amounted to $ 108,000.

 The following
table summarizes additional information concerning warrants outstanding and exercisable at June 30, 2025.

 Schedule of warrants outstanding and exercisable

 Warrants Outstanding

 Warrants Exercisable

 Weighted

 Weighted

 Weighted

 Exercise

 Number

 Remaining

 Exercise

 Number

 Remaining

 Price

 of Shares

 Life (Years)

 Price

 of Shares

 Life (Years)

 $
 0.013

 10,700,000

 4.39

 $
 0.013

 10,700,000

 4.39

 $
 0.016

 5,000,000

 4.64

 0.016

 5,000,000

 4.64

 $
 0.017

 4,500,000

 4.67

 0.017

 4,500,000

 4.67

 $
 0.030

 5,000,000

 4.51

 0.030

 5,000,000

 4.51

 $
 0.090

 23,841,323

 1.00

 0.090

 23,841,323

 1.00

 49,041,323

 2.81

 $
 0.053

 49,041,323

 2.81

 Note 8 - Income Taxes

 For the year
ended June 30, 2025 the Company recorded no provision for income taxes due to the application of the Company's available Federal
and State net operating loss (NOL) carryforwards that are available to reduce taxable income. For the year ended June 30, 2024 the Company
recorded no provision for income taxes due to the Company's taxable net loss position.

 A reconciliation
of the effective income tax to statutory US federal income tax is as follows:

 Schedule of reconciliation
of effective income tax

 2025

 2024

 Federal statutory rate

 21 %

 21 %

 State income taxes, net of Federal benefit

 7 %

 7 %

 Net operating loss utilized

 ( 28 %

)

 ( 28 %

)

 Prior year net operating loss true up

 11 %

 ( 93 %

)

 Valuation allowance

 ( 11 %

)

 93 %

 Income tax provision

 –

 –

 Deferred income
taxes result from temporary differences in the recognition of income and expenses for the financial reporting purposes and for tax purposes.
The components of deferred tax assets are presented below.

 At June 30,
2025, the Company had available Federal NOL carryforwards of approximately $ 10.6 million that are available to reduce future
taxable income. The Federal NOL carry forward of approximately $8.5 million expires through 2037, the remaining NOL of $2.1 million
has no expiry date. The NOLs are subject to statutory limitations under Internal Revenue
Code Section 382 regarding substantial changes in ownership of companies with loss carry forwards.

 At June 30, 2025 and 2024, significant
component of the Company's deferred tax assets and liabilities are as follows:

 Schedule of deferred tax assets and liabilities

 2025

 2024

 Net Operating loss carryforwards

 $
 2,956,000

 $
 2,971,000

 Stock compensation expense

 1,018,000

 962,000

 Total net deferred tax assets

 3,974,000

 3,933,000

 Less valuation discount

 ( 3,974,000
)

 ( 3,933,000
)

 Net deferred tax assets

 $
 –

 $
 –

 The provisions
of ASC Topic 740, Accounting for Income Taxes, require an assessment of both positive and negative evidence when determining whether it
is more likely than not that deferred tax assets are recoverable. For the years ended June 30, 2025 and 2024, based on all available objective
evidence, including the existence of cumulative losses, the Company determined that it was more likely than not that the net deferred
tax assets were not fully realizable. Accordingly, the Company established a full valuation allowance against its net deferred tax assets.
The Company intends to maintain a full valuation allowance on net deferred tax assets until sufficient positive evidence exists to support
reversal of the valuation allowance.

 Accounting rules prescribes a recognition threshold
that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement,
classification, interest and penalties, accounting in interim periods, disclosure and transition issues. The Company classifies interest
and penalties as a component of interest and other expenses. To date, there have been no interest or penalties assessed or paid.

 The Company measures and records uncertain tax positions
by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in
a tax return. Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue
to be recognized.

 Our income tax filings are periodically examined by
various U.S. federal and state jurisdictions. There are no open examinations by federal and state income tax jurisdictions. The Company's
U.S. federal income tax return remains open to examination for the years ended June 30, 2022 through June 30, 2025.

 Note
9 – Commitments and Contingencies

 Royalty Agreements

 On July 1, 2008,
the Company's wholly owned subsidiary entered into Patent Assignment Agreements with two parties, its President as well as its former
Chief Executive Officer (CEO) and current Technology Senior Manager, where certain devices and methods involved in the hydrodynamic cavitation
processes invented by the President and former CEO/ current Technology Senior Manager have been assigned to the Company. In exchange,
the Company agreed to pay a royalty of 5% of gross revenues to each of the President and former CEO/ current Technology Senior Manager
for licensing of the technology and leasing of the related equipment embodying the technology. These agreements were subsequently assigned
to Cavitation Technologies on May 13, 2010. The Company's former CEO/ current Technology Senior Manager and President both
waived their rights to receive royalty payments that have accrued, or that may accrue, on any gross revenue generated through June 30,
2025 and 2024.

 On April 30,
2008 (as amended November 22, 2010), the Company's wholly owned subsidiary entered into an employment agreement with the Director
of Chemical and Analytical Department (the "Inventor") providing that the Inventor shall receive an amount equal to 5% of
actual gross royalties received from the royalty stream in the first year in which the Company receives royalty payments from the patent
which the Inventor was the legally named inventor, and 3% of actual gross royalties received by the Company resulting from the patent
in each subsequent year. As of June 30, 2025, and 2024 no patents have been granted in which this person is the legally named inventor.

 Note 10 – Subsequent
events

has evaluated subsequent events through the date the financial statements were issued and did not identify any subsequent events that
would have required adjustment or disclosure in the financial statements.

 ITEM 9. CHANGES IN AND DISAGREEMENTS
WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 None.

 ITEM 9A. CONTROLS
AND PROCEDURES

 Disclosure Controls and
Procedures

 In accordance with rule 13a-15(a),
our management must maintain disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities and Exchange Act of 1934,
or the Exchange Act, to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit
under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange
Commission rules and forms, and accumulated and communicated to our management, including our principal executive officer and principal
financial officer, as appropriate to allow timely decisions regarding required disclosure.

 In accordance with Rule 13a-15(b)
and (c), management must also evaluate the effectiveness of these disclosure control and procedures at the end of each fiscal year. As
of June 30, 2025, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and
principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that
evaluation, our principal executive officer and principal financial officer concluded that these disclosure controls and procedures were
not effective as of June 30, 2025.

 Report of Management on Internal Control over
Financial Reporting

 Management is responsible
for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange Act.
Our internal control over financial reporting is designed under the supervision of our principal executive and principal financial officer,
and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles
and includes those policies and procedures that:

 (i) pertain to the maintenance
of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;

 (ii) provide reasonable assurance
that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts
and expenditures are being made only in accordance with authorizations of our management and directors; and

 (iii) provide reasonable
assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material
effect on the financial statements.

 Under the supervision and
with the participation of our management, including our Principal Executive Officer and Principal Financial Officer, we conducted an evaluation
of the effectiveness of our internal controls and procedures, (as defined under Rule 13a-15(e) and Rule 15d-15(e) promulgated under the
Securities Exchange Act of 1934, as amended (Exchange Act)) as of the year ended June 30, 2025. Management conducted as assessment of
our internal control over financial reporting based on the framework and criteria established by the Committee of Sponsoring Organizations
of the Treadway Commission ("COSO") in Internal Control-Integrated Framework (2013). Our management concluded that as of June
30, 2025, our internal control over financial reporting was not effective, and that material weaknesses existed in the following areas
as of June 30, 2025:

 1.

 We do not employ full time in-house personnel with the technical knowledge to identify and address some of the reporting issues surrounding certain complex or non-routine transactions. With respect to material, complex and non-routine transactions, management has and will continue to seek guidance from third-party experts and/or consultants to gain a thorough understanding of these transactions;

 2.

 We have ineffective controls over segregation of duties due to limited resources and number of employees; and

 3.

 The Company did not maintain a functioning independent audit committee.

 We are in the continuous
process of improving our internal control over financial reporting in an effort to eliminate these material weaknesses through improved
supervision and training of our staff, but additional effort is needed to fully remedy these deficiencies. We intend to hire the necessary
staff to address the weaknesses once additional capital is obtained which will allow full operations to commence. Because of its inherent
limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined
to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

 Changes in Internal Control
over Financial Reporting

 There have been no changes
in our internal control over financial reporting during the year ended June 30, 2025 that materially affected, or are reasonably likely
to materially affect, our internal control over financial reporting.

 Attestation

 Pursuant to Item 308(b) of
Regulation S-K, as amended by the Dodd-Frank Wall Street Reform and Consumer Protection Act (Wall Street Reform Act), this report does
not include an attestation report of the Company's registered public accounting firm regarding internal control over financial reporting.
The Wall Street Reform Act permanently exempts small public companies from the requirement to obtain an external audit on the effectiveness
of internal financial reporting controls.

 ITEM 9B. OTHER
INFORMATION

 During the quarter ended
June 30, 2025, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1
trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.

 We
do not maintain insider trading policies and procedures governing the purchase, sale, and/or other dispositions of our securities by our
directors, officers, and employees that we believe are reasonably designed to promote compliance with insider trading laws, rules, and
regulations applicable to us. We have failed to do so due to limited number of members of management, limited resources, and the limited
equity awards granted to management.

 ITEM 9C. DISCLOSURE
REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTION

 Not applicable.

 ITEM 10. DIRECTORS,
EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 Person

 Age

 Position

 Naum Voloshin

 President, PEO, Principal Accounting Officer Secretary and Director

 Peter N. Christos

 Director

 Jerry Bailey PhD

 Director

 Naum Voloshin. Mr.
Voloshin has over 30 years of experience in investment banking, business operations and marketing. Prior to joining CTi, Mr. Voloshin
has worked for several developmental stage companies in US, Europe and Asia. The scope of his duties was to provide management, financial
reporting, funding, and marketing expertise.

 Jerry Bailey PhD. Mr.
Bailey has over 50 years of experience in the international petroleum industry. He is a former President of Exxon - Arabian Gulf and prior
to that, served in various operating capacities for major oil producers throughout the Middle East and in the U.S. onshore and offshore
sectors. Dr. Bailey is currently the Chairman of Bailey Petroleum, LLC, a consulting firm for major oil and gas exploration and development
corporations. In addition, during his extensive career, Dr. Bailey has served in a variety of C-Suite and Board capacities for several
oil & gas enterprises. Dr. Bailey holds a BS Degree in Chemical Engineering from the University of Houston, an MS Degree in Chemical
Engineering from the New Jersey Institute of Technology, a PhD Degree from Columbia Pacific University and is a graduate of Engineering
Doctoral Studies from Lamar University.

 Peter N. Christos. Mr.
Christos has over 30 years of Wall Street experience in corporate finance, serving on the boards of numerous private and listed companies,
managing, and advising large scale enterprises as well as early-stage start-ups.

 Family Relationships

 Roman Gordon is a founder
and current Global Technology Manager of the Company. He was a former member of the Company's Board of Directors and Chief Technology
Officer up to July 15, 2016. He is also the brother of Mr. Igor Gorodnitsky, our former President, Principal Executive Officer and member
of the Company's Board of Directors.

 Section 16(a) Beneficial Ownership Reporting
Compliance

 Section 16(a) of the Securities
Exchange Act of 1934, as amended, requires our executive officers, directors, persons who own more than 10% of our common stock, and immediate
family members living in the same household to file an Initial Statement of Beneficial Ownership on Form 3 and changes in ownership on
Form 4 with the Securities and Exchange Commission (the "SEC"). Such "insiders" are required by SEC rules to furnish
us with copies of all Section 16(a) forms they file.

 Based on a review of Forms
3, 4, and 5 and amendments thereto furnished to us during fiscal 2020 updated forms were filed, ended June 30, 2024, there were no delinquent
forms filed during the year.

 Director Independence

 Although our common stock
is not listed on a national securities exchange, for purposes of independence we use the definition of independence applied by the NASDAQ
stock market. The Board has determined that Mr. Bailey and Mr. Christos are "independent" in accordance with such definition.
Mr. Voloshin is not independent due to his current positions with the Company.

 Code of Ethics

 We have adopted a Code of
Business Conduct and Ethics that applies to all officers, directors and employees. A copy may also be obtained free of charge by mailing
a request in writing to: Cavitation Technologies, Inc., 10019 Canoga Ave., Chatsworth, CA 91311 USA. If we make any substantive amendments
to the Code of Business Conduct and Ethics or grant any waiver from a provision of the Code to any executive officer or director, we will
promptly disclose the nature of the amendment or waiver in a current report on Form 8-K.

 ITEM 11. EXECUTIVE COMPENSATION

 Summary Compensation Table

 The following table sets
forth a summary of cash and non-cash compensation awarded, earned or paid for services rendered to us during the years ended June 30,
2025 and 2024 by our "named executive officers," consisting of (i) each individual serving as principal executive officer,
and (ii) our Chief Financial Officer/Chief Operating Officer, our other executive officer.

 Year

 Salary

 Bonus

 Stock Awards

 Warrant Awards

 Non-Equity
 Incentive

 Plan

 Compensation

 Changes
 in

 Pension Value

 and

 Non-Qualified

 Deferred

 Compensation

 All

 Other Compensation

 Totals

 Naum Voloshin

 2025

 $

 187,200

 $

 –

 $

 –

 $

 39,200

 $

 –

 $

 –

 $

 –

 $

 226,400

 Principal Executive & Principal Accounting
 Officer

 2024

 $

 166,305

 $

 –

 $

 –

 $

 –

 $

 –

 $

 –

 $

 –

 $

 166,305

 James W. Creamer

 2025

 $

 –

 $

 –

 $

 –

 $

 –

 $

 –

 $

 –

 $

 –

 $

 –

 Chief Financial Officer (1)

 2024

 $

 20,000

 $

 –

 $

 –

 $

 –

 $

 –

 $

 –

 $

 –

 $

 20,000

 (1)

 Mr. Creamer was named the Company's Chief Financial Officer on October 21, 2022 and resigned from that position on September 14, 2023.

 Outstanding Equity Awards at Fiscal Year-End

 The table below reflects
all outstanding equity awards made to each of the named executive officers that are outstanding as of June 30, 2025.

 Restricted Stock Awards

 Name

 Restricted Stock grant date

 Number of securities Underlying Restricted Stock Awards # Exercisable

 Number of securities Underlying Restricted Stock Awards # Unexercisable

 Restricted Stock Awards Grant Price

 Naum Voloshin

 6/21/2022

 4,000,000

 –

 0.05

 Principal executive and Principal Accounting Officer

 The fair value of each restricted
stock grant is the market value of the stock on the grant date.

 Employment Agreements

 Our executive officers work
as at-will employees.

 Code Section 162(m)
Provisions

 Section 162(m) of the
U.S. Internal Revenue Code, or the Code, generally disallows a tax deduction to public companies for compensation in excess of $1 million
paid to the Chief Executive Officer or any of the four most highly compensated officers. Performance-based compensation arrangements may
qualify for an exemption from the deduction limit if they satisfy various requirements under Section 162(m). Although we consider
the impact of this rule when developing and implementing our executive compensation programs, we believe it is important to preserve flexibility
in designing compensation programs. Accordingly, we have not adopted a policy that all compensation must qualify as deductible under Section 162(m)
of the Code. While our stock options are intended to qualify as "performance-based compensation" (as defined by the Code),
amounts paid under our other compensation programs may not qualify as such.

 2023 Director Compensation

 The following table sets
forth information for the fiscal year ended June 30, 2025 regarding the compensation of our directors who at June 30, 2025 were not also
named executive officers.

 Fees

 Non-equity

 Earned

 inventive

 Non-qualified

 All

 or paid

 Stock

 Option

 plan

 deferred

 other

 in cash

 Awards

 Awards

 compensation

 compensation

 compensation

 Total

 Name

 ($)

 ($)

 ($)

 ($)

 Earnings

 ($)

 ($)

 James Fuller

 $
 –

 $
 –

 $
 –

 $
 –

 $
 –

 $
 –

 $
 –

 Jerry Bailey

 $
 –

 $

 $
 –

 $
 –

 $
 –

 $
 5,000

 $
 15,000

 Peter Christos

 $
 –

 $

 $
 –

 $
 –

 $
 –

 $
 –

 $

 As of June 30, 2025, the
following table sets forth the number of aggregate outstanding option awards held by each of our directors who were not also named executive
officers:

 Aggregate

 Number of

 Name

 Option Awards

 –

 Granting of Certain Equity Awards Close in Time to the Release
of Material Nonpublic Information

 We do not grant equity awards in
anticipation of the release of material nonpublic information that is likely to result in changes to the price of our common
stock, and do not time the public release of such information based on award grant dates. During the last completed fiscal year, we
have not made awards to any named executive officer or director during the period beginning four business days before and ending one
business day after the filing of a period report on Form 10-Q or Form 10-K or the filing or furnishing of a current report on Form
8-K, and we have not timed the disclosure of material nonpublic information for the purpose of affecting the value of executive
compensation.

 ITEM 12. SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

 The following table provides information regarding
the beneficial ownership of our common stock as of September 26, 2024, (the "Evaluation Date") by: (i) each of our current
directors, (ii) each of our named executive officers, and (iii) all such directors and executive officers as a group. We know
of no other person or group of affiliated persons who beneficially own more than five percent of our common stock. The table is based
upon information supplied by our officers, directors and principal stockholders and a review of Schedules 13D and 13G, if any, filed with
the SEC. Unless otherwise indicated in the footnotes to the table and subject to community property laws where applicable, we believe
that each of the stockholders named in the table has sole voting and investment power with respect to the shares indicated as beneficially
owned.

 Applicable percentages are
based on 284,289,740 shares outstanding as of the Evaluation Date, adjusted as required by rules promulgated by the SEC. These rules generally
attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those
securities. In addition, the rules include shares of our common stock issuable pursuant to the exercise of stock options or warrants that
are either immediately exercisable or exercisable within 60 days of the Evaluation Date. These shares are deemed to be outstanding and
beneficially owned by the person holding those options for the purpose of computing the percentage ownership of that person, but they
are not treated as outstanding for the purpose of computing the percentage ownership of any other person.

 Amount and

 Nature of

 Beneficial

 Percent of

 Name of Beneficial Owner

 Ownership

 Class (1)

 Naum Voloshin

 (2)

 19, 212,390

 6.4

 %

 President, Principal Executive Officer, Principal Accounting Officer and Director

 James Fuller

 (3)

 2,337,500

 *

 Chairman of Audit Committee, Director (Resigned effective August 22, 2024)

 Dr. Gerald Bailey

 (4)

 1,400,000

 *

 Director

 Dr. Peter Christos

 (5)

 1,000,000

 *

 Director

 Directors and Officers

 23,949,890

 7.9

 %

 (as a group, four individuals)

 *

 Less than 1%

 (1)

 Unless otherwise set forth below, the mailing address of Executive Officers, Directors and 5% or greater holders is in care of the Company.

 (2)

 Consists of 10,212,390 shares of common stock, including 4,000,000 restricted shares granted to Mr. Voloshin on June 21, 2022 and warrants exercisable for 9,000,000 shares of common stock.

 (3)

 Consists of 837,500 shares of common stock and warrants exercisable for 1,500,000 shares of common stock, all of which are vested.

 (4)

 Consists of warrants exercisable for 1,400,000 shares of common stock.

 (5)

 Consists of warrants exercisable for 1,000,000 shares of common stock.

 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

 Certain Related Party Transactions

 Since the beginning of our
last fiscal year, there has not been, and there is not currently proposed, any transaction or series of similar transactions to which
we were or will be a party in which the amount involved exceeded or will exceed the lesser of $120,000 or one percent of the average of
our total assets at year-end for the last two completed fiscal years and in which any of our directors, executive officers, holders of
more than five percent of any class of our voting securities or any member of the immediate family of the foregoing persons had or will
have a direct or indirect material interest.

 Accrued Payroll and Payroll Taxes

 As of June 30, 2024, the Company had accrued unpaid
salaries to officers and former officers amounting to $ $414,000.

 In February 2025, the Company settled with these
former officer and current officer to extinguish the accrued payroll and payroll related taxes amounting to $425,000 and unpaid health
insurance and cellphone reimbursements recorded in prior years totaling $36,000 for a total liability of $461,000. As part of the settlement,
the Company issued 4,666,600 shares of common stock with a fair value of $90,000 and warrants to purchase 5,000,000 shares of
common stock. The warrants are fully vested, exercisable at $0.016 per share and will expire in five years. The estimated fair value of
these warrants amounted to $100,000 using the Black Scholes Option Pricing Model using the following inputs (i) stock price at the
date of grant of $0.020; (ii) risk free interest rate of 4.37% based on rates established by the Federal Reserve Bank; (iii) expected
volatility 290% based on historical volatility of the Company's common stock commensurate with the expected life of the warrants;
(iv) expected life of 5 years based on the contractual life; and (v) dividend yield of 0% based on no dividends paid or expected to be
paid. Pursuant to current accounting and SEC guidelines and regulations with regards to related party transactions, the Company accounted
for the difference of $271,000 between the carrying amount of the accrued payroll and other liability of $461,000 and the fair value of
the common stock and warrants issued of $190,000 as capital contribution.

 Cameo USA LLC

 In fiscal 2014, Roman Gordon,
one of the Company's shareholders and a former officer, formed a company called Cameo USA LLC (Cameo). Since its formation, Cameo
has had no revenue, no operations, and has had no assets or liabilities. On June 4, 2018, Mr. Gordon contributed his 100% interest in
Cameo to the Company. As Mr. Gordon had no basis in his investment in Cameo, there was no value assigned to the contribution of Cameo.
Subsequent to the contribution of Cameo to the Company, Cameo was sold to Alchemy Beverages Inc.

 Director Independence

 As our common stock is currently
traded on the OTC Bulletin Board, we are not subject to the rules of any national securities exchange which require that a majority of
a listed company's directors and specified committees of the board of directors meet independence standards prescribed by such rules.
For the purpose of preparing the disclosures in this Report on Form 10-K regarding director independence, we have used the definition
of "independent director" set forth in the Marketplace Rules of The NASDAQ, which defines an "independent director"
generally as a person other than an executive officer or employee of the Company or any other individual having a relationship which,
in the opinion of the Company's board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities
of a director. Consistent with these standards, we believe that Dr. Jerry Bailey and Dr. Peter Christos are Independent directors.

 ITEM 14. PRINCIPAL ACCOUNTING FEES
AND SERVICES

 Independent Registered Public Accounting Firm's
Fee Summary

 The following table provides
information regarding the fees billed to us by Weinberg & Company, P.A. for the years ended June 30, 2025 and 2024. All fees described
below were approved by the Board:

 2025

 2024

 Audit Fees and Expenses (1)

 $
 60,000

 $
 86,000

 All Other Fees

 $
 –

 $
 9,000

 (1)

 Audit fees and expenses were for professional services rendered for the audit and reviews of the consolidated financial statements of the Company, professional services rendered for issuance of consents and assistance with review of documents filed with the SEC.

 Pre-Approval Policies
and Procedures

 Consistent with SEC policies
regarding auditor independence, the Audit Committee has responsibility for appointing, setting compensation and overseeing the work of
the independent registered public accounting firm. In recognition of this responsibility, the Audit Committee has established a policy
to pre-approve all audit and permissible non-audit services provided by the independent registered public accounting firm.

 Prior to the engagement of
the independent registered public accounting firm for the next year's audit, management will submit a list of services and related
fees expected to be rendered during that year for audit services, audit-related services, tax services and other fees to the Audit Committee
for approval.

 ITEM 15. EXHIBITS, FINANCIAL STATEMENT
SCHEDULES

 (a) The following documents are filed as part
of this annual report on Form 10-K:

 1. Financial Statements

 The financial statements
are filed as part of this report under Item 8 "Financial Statements and Supplementary Data".

 2. Financial Statement Schedules

 All other schedules are omitted
because they are not applicable or the required information is presented in the financial statements and notes thereto.

 3. Exhibits

 The exhibits required by Item 601 of Regulation
S-K are included in Item 15(b) below.

 (b) - Exhibits.

 Incorporated by Reference

 Exhibit

 Filed

 Period

 Filing

 Number

 Exhibit Description

 Herewith

 Form

 Ending

 Exhibit

 Date

 3(i)(a)

 Articles of Incorporation - original name of Bioenergy, Inc.

 SB-2

 N/A

 3.1

 October 19, 2006

 3(i)(b)

 Articles of Incorporation - Amended and Restated

 December 31, 2008

 3.1

 February 17, 2009

 3(i)(c)

 Articles of Incorporation - Amended and Restated

 3.1

 May 14, 2009

 3(i)(d)

 Articles of Incorporation - Amended; increase in authorized shares

 N/A

 N/A

 October 29, 2009

 3(i)(e)

 Articles of Incorporation - Certificate of Amendment; forward split

 December 31, 2009

 3.1

 November 16, 2009

 10.1

 Patent Assignment Agreement between the Company and Roman Gordon dated July 1, 2008.

 10.1

 May 18, 2010

 10.2

 Patent Assignment Agreement between the Company and Igor Gorodnitsky dated July 1, 2008.

 10.2

 May 18, 2010

 10.3

 Assignment of Patent Assignment Agreement between the Company and Roman Gordon

 10.3

 May 18, 2010

 10.4

 Assignment of Patent Assignment Agreement between the Company and Igor Gorodnitsky

 10.4

 May 18, 2010

 10.5

 Employment Agreement between the Company and Roman Gordon date March 17, 2008

 10K/A

 10.3

 October 20, 2011

 10.6

 Employment Agreement between the Company and Igor Gorodnitsky dated March 17, 2008

 10K/A

 10.4

 October 20, 2011

 10.7

 Employment Agreement with R.L. Hartshorn dated Sept. 22, 2009

 December 31, 2011

 10.7

 February 10, 2012

 10.8

 Employment and Confidentiality and Invention Assignment Agreement between the Company and Varvara Grichko dated April 30, 2008

 December 31, 2010

 10.3

 February 11, 2011

 10.9

 Board of Director Agreement - James Fuller

 December 31, 2011

 10.12

 October 20, 2011

 Incorporated by Reference

 Exhibit

 Filed

 Period

 Filing

 Number

 Exhibit Description

 Herewith

 Form

 Ending

 Exhibit

 Date

 10.1

 Technology and License Agreement with Desmet Ballestra dated 14 May 2012

 June 30, 2012

 10.1

 October 15, 2012

 10.11

 Convertible Note Payable - Prolific Group LLC - $25,000

 December 31, 2011

 10.4

 February 10, 2012

 10.12

 Convertible Note Payable - Tripod Group LLC - $30,000

 December 31, 2011

 10.41

 February 10, 2012

 14.1

 Code of Business Conduct and Ethics*

 June 30, 2011

 14.1

 September 28, 2011

 31.1

 Certificate of Principal Executive Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002

 X

 31.2

 Certificate of Principal Financial Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002

 X

 32.1

 Certification of Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 X

 32.2

 Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 X

 101.INS

 X

 101.SCH

 X

 101.CAL

 X

 101.DEF

 X

 101.LAB

 X

 101.PRE

 X

 X

 *

 In accordance with Regulation S-K 406 of the Securities Act of 1934, we undertake to provide to any person without charge, upon request, a copy of our "Code of Business Conduct and Ethics". A copy may be requested by sending an email to info@cavitationtechnologies.com.

 (c) - Financial Statement Schedules

 See Item (a) 2 above.

 ITEM 16. FORM 10-K
SUMMARY

 Not applicable.

 SIGNATURES

 PURSUANT TO THE REQUIREMENTS
OF THE SECURITIES EXCHANGE ACT OF 1934, THIS REPORT HAS BEEN SIGNED BELOW BY THE FOLLOWING PERSONS ON BEHALF OF THE REGISTRANT AND IN
THE CAPACITIES AND ON THE DATES INDICATED

 SIGNATURE

 TITLE

 DATE

 /s/ N. Voloshin

 President; Member of Board of Directors

 N. Voloshin

 (Principal Executive Officer)

 /s/ N. Voloshin

 Chief Financial Officer

 N. Voloshin

 (Principal Financial Officer)

 /s/ Dr. Gerald Bailey

 Independent Director

 Dr. Gerald Bailey

 /s/ Peter N Christos

 Independent Director

 Peter N. Christos